Parsippany, NJ – October 3, 2023 – Ferring Pharmaceuticals today announced it will present two analyses of data for REBYOTA® (fecal…
Fortune’s “Change the World” List recognises companies that have had a positive social impact through activities that are part of…
Parsippany, NJ – September 21, 2023 – Ferring Pharmaceuticals today announced it will present analyses of data for REBYOTA® (fecal microbiota,…
Urologists treating eligible high-risk bladder cancer patients at participating early experience program clinics in the U.S. can now prescribe the…
Royalty Pharma to pay Ferring $300 million upfront and a potential $200 million milestone payment in exchange for royalties on…
Integrated analysis is the largest safety evaluation to date of any microbiota-based live biotherapeutic and includes safety data for up…
Parsippany, NJ – June 26, 2023 – Ferring Pharmaceuticals today announced it will make the intravesical gene-therapy ADSTILADRIN® (nadofaragene firadenovec-vncg) available…
Approval of Prior-Approval Supplement will help to ensure the future, long-term supply and clinical activities for Ferring’s novel intravesical gene…
The primary endpoint was met: SI-6603 showed statistically significant improvement in worst leg pain score versus control at 13 weeks…
Data presentations highlight Ferring’s microbiome leadership and commitment to ongoing research Analyses review safety and efficacy data across various patient…